News und Analysen
Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Affirm (NASDAQ: AFRM) has seen wild fluctuations in its stock price over the past three years. Shares peaked at nearly $169 in November 2021 but are down 80% from that level today. However
Expanding Its "Partner Ecosystem" Could Reignite Growth at OKTA
Okta’s (NASDAQ: OKTA) stock price has had a difficult few years. Since August of 2021, shares are down around 63%. However, over the past 52 weeks, the stock is recovering, up 34%. The
Buy the Dip In NVIDIA, But Be Prepared for Volatility
Given the trends and consensus forecast, NVIDIA (NASDAQ: NVDA) had a smoking hot quarter, and new stock price highs will likely come soon, probably before the end of the year. The catch is that
Netflix Stock Is Back At Highs With A Lot More To Come
And just like that, the streaming giant and tech titan Netflix Inc (NASDAQ: NFLX) is back at all-time highs. It will be a welcome occasion for investors and long-term fans who've been following
3 Best Growth Stocks to Own for the Next 10 Years
During times of market volatility, it’s always good for long-term investors to take a breath and zoom out. That doesn’t mean getting out of the markets as fast as possible. Instead, it means
Workday Stock Perks Up on Results; New Highs Possible This Year
Workday (NASDAQ: WDAY) stock price is up 30% from the recent low and will head higher because of its results, operational quality, and analysts' sentiment. The combination has the market on
Don’t Let Peloton Take You For a Ride: What You Need to Know
Peloton (NASDAQ: PTON) wowed the market with its FQ4 results, sending its shares up nearly 50% in two days. This indicates a dynamic shift that could increase its price over the coming quarters
Intuit Stock Drops Sharply on Profit Concerns: Is It a Buy?
On a day when stocks rallied on expectations of lower interest rates, Intuit Inc. (NASDAQ: INTU) was the biggest loser on the S&P 500. Shares of the financial services company known for the
3 Stocks Mega Investors Are Buying Right Now
During the past two weeks, investors have scrutinized the stock market closely, especially as the S&P 500 just recovered from one of its worst selloffs in 2024. There is doubt as to whether any
Meta And The Case For A 20% Rally Before Christmas
Despite falling close to 20% during the late July / early August selloff, shares of tech titan Meta Inc (NASDAQ: META) have already recovered. They’ve done more than just recover, in fact, as they
NVIDIA: Analysts Bullish Ahead of Earnings - is it a Buy Now?
As NVIDIA (NASDAQ: NVDA) prepares to report its fiscal second-quarter earnings on Wednesday, August 28, after the market close, a surge of analyst upgrades has captured investor attention. With
3 Surging Call Options and What They Mean for Investors
Investing in stock options can also bring extended rewards at the expense of higher risks. The main risks come through timing, as investors need to have the direction and timing correct for an
Rate Cuts a Near Certainty: 3 Stocks You Might Have Missed
With cooling inflation and moderating economic growth, the current economic environment strongly suggests that the Federal Reserve is on the verge of cutting interest rates. Market analysts are
Lumen: Among Top Performers Last Month, Still Has Warning Signs
Lumen Technologies (NYSE: LUMN) has experienced skyrocketing share price in the last month, making it one of the top-performing stocks based on total 30-day returns in the area of 323% as of
Baidu's Strong Quarter Proves a Smart Pick for Michael Burry
Recently, investors have had the chance to gain insight into the portfolios of Wall Street’s mega investors, from Warren Buffett and his multi-billion dollar positions and portfolio shifts to
Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Intuit Inc. (NASDAQ: INTU) is the financial technology powerhouse behind TurboTax, Credit Karma, QuickBooks, and Mailchimp. The company continues to demonstrate its dominance in the market with
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an
Moderna erhält von der Europäischen Kommission die Genehmigung für den RSV-Impfstoff mRESVIA(R)
CAMBRIDGE, MASSACHUSSETTS / ACCESSWIRE / 23. August 2024 / Moderna, Inc. (NASDAQ: MRNA) hat heute bekannt gegeben, dass die Europäische Kommission (EC) die Marktzulassung für mRESVIA
4 No-Brainer Stocks to Hold This Fall for Steady Gains
When markets get volatile, investors of any size and background tend toward certainty in business models and predictability in cash flows. Fitting this category are stocks in the consumer staples
Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
The late July and early August sell-off may have spooked many investors, but it also opened up some very tempting entry opportunities. Already, we’re seeing market-wide recovery rallies reclaim
Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?
Stanley Druckenmiller, a renowned investor with a stellar track record, has made headlines with his family office, Duquesne, selling its position in NVIDIA (NASDAQ: NVDA) after accurately
Is AMD Closing the Gap with Nvidia After its Recent Acquisition?
Advanced Micro Devices (NASDAQ: AMD) recently made an important announcement in the firm's efforts to catch up with Nvidia (NASDAQ:NVDA) in the data center market. The semiconductor company
Are Tech Stocks Making a Comeback? 3 Top Picks Leading the Way
After the brief sell-off in the S&P 500 sparked by the so-called “carry trade” between the U.S. dollar and the Japanese yen, most investors thought that the bullish wave taking over the technology
3 High P/E Stocks That Are Still Worth Buying Right Now
One of the most common fundamental metrics that investors use to analyze stocks is the price-to-earnings (P/E) ratio. This ratio tells you how much you’re paying for $1 of a company’s profits. The
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. The company disappointed investors when it revised